^
    over2years
    #ASCO23 #BreastCancer #OncoAlert Take Home Message 2 Biomarker PENELOPE-B: RCT subanalysis using RaDaR in postoperative PAL. Poor prognosis when ctDNA becomes positive. Low sensitivity for late recurrence. SOFT trial: PAM50 as a prognostic factor, not a predictive factor in… https://t.co/CAaWtnRvWn (@teamoncology)
    Circulating tumor DNA
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • RaDaR™ assay
    over2years
    #ASCO23 #BreastCancer #OncoAlert Take Home Message 2 Biomarker PENELOPE-B: RCT subanalysis using RaDaR in postoperative PAL. Poor prognosis when ctDNA becomes positive. Low sensitivity for late recurrence. SOFT trial: PAM50 as a prognostic factor, not a predictive factor in… https://t.co/SwA9afc0c9 (@teamoncology)
    Circulating tumor DNA
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • RaDaR™ assay
    3years
    Tumor informed highly sensitive ctDNA assay (RaDaR) in TN early stage BC (TN-TRACK study) detects clinical relapse with a longer lead time than dPCR (6 m vs 3 m). We need this kind of data also for luminal disease. #SABCS22 ()
    Clinical • Circulating tumor DNA
    |
    RaDaR™ assay
    over3years
    CHiRP real-world (N=83 w/ ctDNA): ctDNA MRD and late recurr in high-risk HR+/HER2- #bcsm -WES RaDaR assay -6 pts distant recurr: all detected by ctDNA but only 2 w/ 1. sample (& 1 local recurr missed) -2 ctDNA+ pts: not recurred -Med lead time ~12 mon @OncoAlert #ASCO22 ()
    Real-world evidence • Clinical • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    RaDaR™ assay